Stable Intracerebral Transplantation of Neural Stem Cells for the Treatment of Paralysis Due to Ischemic Stroke.

ABSTRACT: NSI-566 is a stable, primary adherent neural stem cell line derived from a single human fetal spinal cord and expanded epigenetically with no genetic modification. This cell line is being tested in clinical trials in the U.S. for treatment of amyotrophic lateral sclerosis and spinal cord injury. In a single-site, phase I study, we evaluated the feasibility and safety of NSI-566 transplantation for the treatment of hemiparesis due to chronic motor stroke and determined the maximum tolerated dose for future trials. Three cohorts (n = 3 per cohort) were transplanted with one-time intracerebral injections of 1.2 × 10⁷ , 2.4 × 10⁷ , or 7.2 × 10⁷  cells. Immunosuppression therapy with tacrolimus was maintained for 28 days. All subjects had sustained chronic motor

SUBMITTER: Zhang G 

PROVIDER: S-EPMC6766600 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature